ABBVIE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
Not Applicable
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT07044687
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Not yet recruiting
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 700
- Registration Number
- NCT07039110
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
Phase 3
Recruiting
- Conditions
- Mid Face Volume Deficit
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT07032597
- Locations
- 🇨🇳
Beijing Hospital /ID# 272476, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital (West) - Xidan Campus /ID# 272480, Beijing, Beijing, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 272631, Wuhan, Hubei, China
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 2
Not yet recruiting
- Conditions
- Gynecologic CancersPlatinum-Sensitive Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer (PSOC)
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT07024784
Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants
Phase 1
Not yet recruiting
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Placebo for ABBV-932
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT07024797
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Phase 2
Not yet recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2025-06-16
- Last Posted Date
- 2025-06-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 140
- Registration Number
- NCT07023289
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
Phase 3
Not yet recruiting
- Conditions
- Alopecia Areata
- Interventions
- Drug: Upadacitinib Placebo
- First Posted Date
- 2025-06-16
- Last Posted Date
- 2025-06-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 123
- Registration Number
- NCT07023302
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Phase 3
Not yet recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: Surabgene Lomparvovec (ABBV-RGX-314)Drug: Ranibizumab Control
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 561
- Registration Number
- NCT07007065
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT07007091
- Locations
- 🇺🇸
Ppd - Las Vegas Research Unit /ID# 276565, Las Vegas, Nevada, United States
🇺🇸Cpmi /Id# 276490, Miami, Florida, United States
🇺🇸Acpru /Id# 276043, Grayslake, Illinois, United States
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 694
- Registration Number
- NCT07005102